Lv2
140 积分 2021-07-22 加入
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
7天前
已完结
生物制剂在系统性红斑狼疮中应用的中国专家共识（2024版）
14天前
已完结
Sequence modeling and design from molecular to genome scale with Evo
1个月前
已完结
Transmembrane domain–driven PD-1 dimers mediate T cell inhibition
1个月前
已完结
Cytokine storm and targeted therapy in hemophagocytic lymphohistiocytosis
2个月前
已完结
Murine Models of Secondary Cytokine Storm Syndromes
3个月前
已完结
Discovery of ABBV-154, an anti-TNF Glucocorticoid Receptor Modulator Immunology Antibody-Drug Conjugate (iADC)
3个月前
已完结
Long-term and sequential treatment for osteoporosis
3个月前
已完结
Additive efficacy of a bispecific anti–TNF/IL-6 nanobody compound in translational models of rheumatoid arthritis
4个月前
已完结
Targeting the TNF and TNFR superfamilies in autoimmune disease and cancer
4个月前
已完结
皖公网安备34019202002308
